Describe a novel use for a kinase inhibitor, imatinib, in young children with a known activated somatic mutation in PDGFR-beta. Two patients with infantile myofibromatosis treated with imatinib. Case description of evaluation, diagnosis and treatment decisions for infantile myfibromatosis of the head and neck. Description of medical therapy for infantile myofibromatosis in these patients. For function threatening myofibromas of a known genotype, in infants, targeted medical therapy is a treatment option.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826127 | PMC |
| http://dx.doi.org/10.1002/ccr3.5382 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A germline PDGFRB splice site variant associated with infantile myofibromatosis and resistance to imatinib.
Genet Med
November 2024
De Duve Institute, University of Louvain, Brussels, Belgium. Electronic address:
Purpose: Infantile myofibromatosis is characterized by the development of myofibroblastic tumors in young children. In most cases, the disease is caused by somatic gain-of-function variants in platelet-derived growth factor (PDGF) receptor beta (PDGFRB). Here, we reported a novel germline intronic PDGFRB variant, c.
View Article and Find Full Text PDFPneumothorax revealing late recurrence of infantile myofibromatosis.
Ann Thorac Med
October 2024
Department of Pulmonology, University Hospital Saint-Luc, Brussels, Belgium.
Adult recurrence of infantile myofibromatosis is exceptional. Here, we report the case of a 23-year-old woman with a late recurrence of infantile myofibromatosis revealed by spontaneous pneumothorax. The chest computed tomography scan found both cavitary and nodular bilateral pulmonary lesions.
View Article and Find Full Text PDFA Rare Case of Infantile Myofibromatosis With Intra Cranial Involvement.
Glob Pediatr Health
August 2024
Hospital IBN SINA, Rabat, Morocco.
Infantile myofibromatosis is a proliferative disorder occurring during infancy and early childhood, marked by the development of nodular or diffuse lesions consisting of various mesenchymal elements. Intracranial involvement is infrequently reported. Here, we present the case of a 3-year-old girl exhibiting a rare manifestation of IM with intracranial parenchymal involvement, displaying a histological pattern documented in existing literature on patients with infantile myofibromatosis.
View Article and Find Full Text PDFLate Relapse in Genetically Determined Infantile Myofibromatosis. A Case Report and Brief Focus on Recurrences.
J Pediatr Hematol Oncol
October 2024
Oncology Unit, IRCCS Giannina Gaslini, Genoa.
Background: Infantile myofibromatosis (IM) is a rare disorder characterized by benign tumors in the skin, subcutaneous tissue, muscle, and occasionally viscera. IM can be hereditary due to PDGFRB or NOTCH3 variants. Treatment is mainly conservative or surgical.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!